Big spleens and hypersplenism: Fix it or forget it?

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Hypersplenism is a common manifestation of portal hypertension in the cirrhotic. More than half of cirrhotics will have low platelet counts, but neutropenia is much less common. Despite being common in the cirrhotic population, the presence of hypersplenism is of little clinical consequence. The presence of hypersplenism suggests more advanced liver disease and an increase in risk of complications, but there is no data showing that correcting the hypersplenism improves patient survival. In most series, the most common indications for treating the hypersplenism is to increase platelet and white blood cell counts to allow for use of drugs that suppress the bone marrow such as interferon alpha and chemotherapeutic agents. There are several approaches used to treat hypersplenism. Portosystemic shunts are of questionable benefit. Splenectomy, either open or laparoscopically, is the most effective but is associated with a significant risk of portal vein thrombosis. Partial splenic artery embolization and radiofrequency ablation are effective methods for treating hypersplenism, but counts tend to fall back to baseline long-term. Pharmacological agents are also effective in increasing platelet counts. Development of direct acting antivirals against hepatitis C will eliminate the most common indication for treatment. We lack controlled trials designed to determine if treating the hypersplenism has benefits other than raising the platelet and white blood cell counts. In the absence of such studies, hypersplenism in most patients should be considered a laboratory abnormality and not treated, in other words forget it.

Original languageEnglish (US)
Pages (from-to)1492-1498
Number of pages7
JournalLiver International
Volume35
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

Hypersplenism
Spleen
Platelet Count
Leukocyte Count
Blood Platelets
Surgical Portasystemic Shunt
Splenic Artery
Portal Hypertension
Splenectomy
Hepatitis C
Portal Vein
Neutropenia
Interferon-alpha
Antiviral Agents
Liver Diseases
Thrombosis
Bone Marrow
Pharmacology

Keywords

  • Hypersplenism
  • Splenectomy
  • Splenomegaly

ASJC Scopus subject areas

  • Hepatology

Cite this

Big spleens and hypersplenism : Fix it or forget it? / Boyer, Thomas D; Habib, Shahid -.

In: Liver International, Vol. 35, No. 5, 01.05.2015, p. 1492-1498.

Research output: Contribution to journalArticle

@article{f7c04a36280b4061af233d5013df4a9c,
title = "Big spleens and hypersplenism: Fix it or forget it?",
abstract = "Hypersplenism is a common manifestation of portal hypertension in the cirrhotic. More than half of cirrhotics will have low platelet counts, but neutropenia is much less common. Despite being common in the cirrhotic population, the presence of hypersplenism is of little clinical consequence. The presence of hypersplenism suggests more advanced liver disease and an increase in risk of complications, but there is no data showing that correcting the hypersplenism improves patient survival. In most series, the most common indications for treating the hypersplenism is to increase platelet and white blood cell counts to allow for use of drugs that suppress the bone marrow such as interferon alpha and chemotherapeutic agents. There are several approaches used to treat hypersplenism. Portosystemic shunts are of questionable benefit. Splenectomy, either open or laparoscopically, is the most effective but is associated with a significant risk of portal vein thrombosis. Partial splenic artery embolization and radiofrequency ablation are effective methods for treating hypersplenism, but counts tend to fall back to baseline long-term. Pharmacological agents are also effective in increasing platelet counts. Development of direct acting antivirals against hepatitis C will eliminate the most common indication for treatment. We lack controlled trials designed to determine if treating the hypersplenism has benefits other than raising the platelet and white blood cell counts. In the absence of such studies, hypersplenism in most patients should be considered a laboratory abnormality and not treated, in other words forget it.",
keywords = "Hypersplenism, Splenectomy, Splenomegaly",
author = "Boyer, {Thomas D} and Habib, {Shahid -}",
year = "2015",
month = "5",
day = "1",
doi = "10.1111/liv.12702",
language = "English (US)",
volume = "35",
pages = "1492--1498",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Big spleens and hypersplenism

T2 - Fix it or forget it?

AU - Boyer, Thomas D

AU - Habib, Shahid -

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Hypersplenism is a common manifestation of portal hypertension in the cirrhotic. More than half of cirrhotics will have low platelet counts, but neutropenia is much less common. Despite being common in the cirrhotic population, the presence of hypersplenism is of little clinical consequence. The presence of hypersplenism suggests more advanced liver disease and an increase in risk of complications, but there is no data showing that correcting the hypersplenism improves patient survival. In most series, the most common indications for treating the hypersplenism is to increase platelet and white blood cell counts to allow for use of drugs that suppress the bone marrow such as interferon alpha and chemotherapeutic agents. There are several approaches used to treat hypersplenism. Portosystemic shunts are of questionable benefit. Splenectomy, either open or laparoscopically, is the most effective but is associated with a significant risk of portal vein thrombosis. Partial splenic artery embolization and radiofrequency ablation are effective methods for treating hypersplenism, but counts tend to fall back to baseline long-term. Pharmacological agents are also effective in increasing platelet counts. Development of direct acting antivirals against hepatitis C will eliminate the most common indication for treatment. We lack controlled trials designed to determine if treating the hypersplenism has benefits other than raising the platelet and white blood cell counts. In the absence of such studies, hypersplenism in most patients should be considered a laboratory abnormality and not treated, in other words forget it.

AB - Hypersplenism is a common manifestation of portal hypertension in the cirrhotic. More than half of cirrhotics will have low platelet counts, but neutropenia is much less common. Despite being common in the cirrhotic population, the presence of hypersplenism is of little clinical consequence. The presence of hypersplenism suggests more advanced liver disease and an increase in risk of complications, but there is no data showing that correcting the hypersplenism improves patient survival. In most series, the most common indications for treating the hypersplenism is to increase platelet and white blood cell counts to allow for use of drugs that suppress the bone marrow such as interferon alpha and chemotherapeutic agents. There are several approaches used to treat hypersplenism. Portosystemic shunts are of questionable benefit. Splenectomy, either open or laparoscopically, is the most effective but is associated with a significant risk of portal vein thrombosis. Partial splenic artery embolization and radiofrequency ablation are effective methods for treating hypersplenism, but counts tend to fall back to baseline long-term. Pharmacological agents are also effective in increasing platelet counts. Development of direct acting antivirals against hepatitis C will eliminate the most common indication for treatment. We lack controlled trials designed to determine if treating the hypersplenism has benefits other than raising the platelet and white blood cell counts. In the absence of such studies, hypersplenism in most patients should be considered a laboratory abnormality and not treated, in other words forget it.

KW - Hypersplenism

KW - Splenectomy

KW - Splenomegaly

UR - http://www.scopus.com/inward/record.url?scp=84927593125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927593125&partnerID=8YFLogxK

U2 - 10.1111/liv.12702

DO - 10.1111/liv.12702

M3 - Article

C2 - 25312770

AN - SCOPUS:84927593125

VL - 35

SP - 1492

EP - 1498

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 5

ER -